FN Summary: Lead asset (Durlobactam) to treat CRAB is in P3 clinical trials. Existing treatments for CRAB have a 50% mortality rate. Phase 2 results were good and non-inferiority Phase 3 trial is progressing nicely with full enrollment completed in July. Good insider ownership, but is primarily one company who sits on the BOD. Company also has an oral drug to treat gonorrhea, which is also in Phase 3, but Covid seems to be slowing enrollment.
Table of Contents
This company hits most of the right spots.
High Institutional Ownership
Good Phase 2
Plenty of Cash (as of Aug 2021)
Good Insider Ownership
Results on Durlobactam P3 non-inferiority Trial ~ early 4Q 2021
Countdown Timer 👇
Caveat! Stock movement can be very finicky and, at times, seemingly random. This is FN's best explanation of the price movement.
Cash on Hand
Est Monthly Cash Burn
just an estimate
Est Cash End of Aug 2021
Plenty of cash until P3 data catalyst in Q4.
Products & Sales Potential
For Context: Entasis Market Cap ~ $178M as of Sept 24, 2021
Yes, we know. This is the boring part of the page. But, it is also the most important. Read this: Importance of Management
- Manos Perros, Ph.D., has served as our chief executive officer, co-founder and director since May 2015. Prior to this, Dr. Perros worked for AstraZeneca AB as vice president and head of its infection research and early development organization from 2010 to 2015 and as site head for its research center in Waltham, Massachusetts from 2012 to 2015. Prior to joining AstraZeneca, Dr. Perros served as director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as vice-president and chief scientific officer, antivirals, at Pfizer, Inc.
- David Altarac MD, MPA joined Entasis as our Chief Medical Officer in 2020. Prior to this, David was a Senior Vice President and Head of Global Regulatory Affairs, Global Drug Safety and R&D Quality and Compliance at Shire Inc. Prior to joining Shire, David spent two years as VP, Regulatory Affairs at NeoStem, a biopharmaceutical company developing novel, cell-based, individualized therapeutics. Before joining NeoStem, David spent over 13 years at Merck & Company where he served on multiple senior leadership teams. David holds an M.D. degree from New York Medical College, a Master of Public Administration (M.P.A.) degree from New York University, and a B.A. in Chemistry from the State University of New York at Binghamton, New York. David completed his Internal Medicine residency and Infectious Diseases fellowship at Beth Israel Medical Center in New York. David has been the principle and co-investigator on TB, HIV and STD grants funded by the CDC, NIH, and New York State Department of Health. David has held multiple academic, hospital and post graduate teaching appointments during his career and has authored/coauthored numerous scientific publications.
Phase 3 Clinical Trial
Understanding the Phase 2 trial is crucial to anticipate the success of the current Phase 3 trial. Below is a slide taken out of the corporate presentation.
The above slide (middle section) is the only mention of Phase 2 results. The company has not highlighted anything significant as far as efficacy. Therefore, we needed to dig to discern the Phase 2 results.
Here is the Results Abstract of the Phase 2 Trial. (the underlined areas are the most important)
The Phase 2 trial was a non-inferiority trial. This is because Acinetobacter is becoming resisting to existing antibiotics. A new drug is needed to treat this type of infection. This is the primary purpose of Durlobactam.
Phase 3 was designed based on the results of Phase 2 and Phase 1 trials.
Despite being equivalent in efficacy to existing treatment, Durlobactam (SUL-DUR) could have less SAE as well as other benefits. See inside red box below.
ETTX Discussion Forums (listed in order of best DD potential)
Q. What does CRAB stand for
A. Carbapenem- resistant Acinetobacter baumannii, or CRAB, are highly antibiotic-resistant bacteria for which few treatment options exist. Carbapenems are a group of antibiotics often reserved for treating multidrug-resistant A. baumannii infections. Some CRAB are resistant to all available antibiotics. Source
Q. What commercial rights does Entasis have?
A. Entasis has partnered with Chinese-based Zai Lab and theyhave the rights to China and other Asia-Pacific territories. However, Entasis maintains 100% of the commercial rights outside of Asia-Pacific, including Europe and North America.